Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Jun;81(6):904-907.
doi: 10.1002/ana.24940. Epub 2017 Jun 1.

Rigor, reproducibility, and in vitro cerebrospinal fluid assays: The devil in the details

Affiliations
Comment

Rigor, reproducibility, and in vitro cerebrospinal fluid assays: The devil in the details

Olivia A Moody et al. Ann Neurol. 2017 Jun.

Abstract

Divergent results and misinterpretation of non-significant findings remain problematic in science – especially in retrospective, hypothesis generating, translational research. When such divergence occurs, it is imperative that the cause of the divergence be established.

In their recent paper in Annals of Neurology, Dauvilliers et al challenged our earlier finding that cerebrospinal fluid (CSF) from some patients with unexplained excessive daytime sleepiness enhances the activation of GABAA receptors (GABAA-R). They present data from 15 subjects in which they were unable to find evidence of enhanced activation of GABAA receptors. Here we: 1) establish how flaws in Dauvilliers’ experimental design account for this difference; 2) present new data demonstrating the robustness and reproducibility of our methods and 3) summarize the clinical promise of GABAA-R antagonism in treating IH and related disorders.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interests

Nothing to disclose for this work (see ICJME for interests not related to the current work): OAM, ST, MAJ, AFF, DB, LMT, EMH, NF, PS, PSG & JWL AJ, OAM, DBR, JWL and LMT contributed to the conception and design of the study. OAM, ST, MAJ, AFF, AJ, PS, EMH, NF and BC were responsible for acquisition and analysis of the data. AJ, MAJ, OAM, LMT, PSG, JWL, DBR and DB were responsible for drafting the text or preparing the figures.

Figures

Figure 1
Figure 1
A. Example trace of currents recorded from α1β2γ2 GABAARs in response to 10–300μM GABA ± 50% CSF. Dotted lines and arrows mark the degree/direction of modulation. Notice that low ECs result in enhancement while high ECs result in desensitization and inhibition. Scale bar: 5sec, 1000pA. B. Average enhancement (%) measured from peak currents (I): (IGABA+CSF – IGABA)/(IGABA)*100 for each GABA concentration shown in Figure A. (In Figure 1A, notice how enhancement is nearly zero at 30μM and negative beyond that as peaks desensitize, making measurements of enhancement unreliable. C. Enhancement comparison of 32 CSFs in 2 populations of receptors: enhancement of α2β2 receptors determined using planar patch clamp electrophysiology at the University of Queensland (Lynch Lab) and enhancement of α1β2γ2 receptors determined using single electrode patch clamp electrophysiology at Emory University (Jenkins Lab). The line represents the line of identity. D. Average desensitization of peak currents from α1β2γ2 (●) and α2β2γ2 (◊) receptors, calculated as the difference of peak amplitude to the amplitude at the end of each GABA exposure. Linear regressions to calculate desensitization (d%) as a function of log[GABA] for each receptor were: α1: d%=8.67*log[GABA]-11.53 and α2: d%=18.12*log[GABA]-16.68. Effective concentrations for each GABA concentration could be back calculated using Hill=1.36 (α1) and 1.53 (α2) and EC50= 60μM (α1) and 8.8μM (α2) and the Hill equation: I/Imax = [GABA]nH/([GABA]nH + EC50nH). Trace inset of a 2 sec exposure of saturating (300μM) GABA to α2β2γ2 receptors with dotted lines and arrow indicating the degree of desensitization. Scale bar: 1sec, 1000pA. n=24 cells (α1), n=35 cells (α2). Where not shown, the error bars are smaller than the symbol.

Comment in

Comment on

References

    1. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ. 1995;311(7003):485. - PMC - PubMed
    1. Dauvilliers Y, Evangelista E, Lopez R, et al. Absence of gamma-aminobutyric acid-a receptor potentiation in central hypersomnolence disorders. Annals of neurology. 2016;80:259–268. - PubMed
    1. Rye DB, Bliwise DL, Parker K, et al. Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors. Sci Transl Med. 2012;4:161ra151. - PubMed
    1. Balansa W, Islam R, Fontaine F, et al. Sesterterpene glycinyl-lactams: a new class of glycine receptor modulator from Australian marine sponges of the genus Psammocinia. Org Biomol Chem. 2013;11:4695–4701. - PubMed
    1. Billiard M, Sonka K. Idiopathic hypersomnia. Sleep Med Rev. 2016;29:23–33. - PubMed

Publication types